Skin barrier dysfunction and correlation with the onset and progression of psoriasis

• by Ying Wang, Yanyang Liang, Jianxiao Xing, Junqin Li, Kaiming Zhang

• June 30, 2026

Does TYK2/JAK1 Show Potential in Inflammatory Diseases?

Investigational inhibitor was not associated with treatment-related serious adverse events and produced biomarker changes consistent with pathway inhibition in healthy volunteers.

• by Andrea Surnit

• July 6, 2026

• 3 min

Modified Delphi Consensus Recommendations for the Management of Psoriasis in Asia–Pacific

• by Yoo Sang Baek, Siew Eng Choon, Peter Anthony Foley, Tsen Fang Tsai, Jianzhong Zhang, Yukie Yamaguchi

• July 1, 2026

Skin Impacts and Tradeoffs of GLP-1 Therapy: Improved Patient-Reported Outcomes of Inflammatory Skin Disease in the Era of “Ozempic Face”

• by Saroja Rao, Isabella Midura, Kathyana P. Santiago Mangual, Leon I. Igel, Katherine H. Saunders, Jocelyn Carter, Jenny E. Murase, Arianne Shadi Kourosh

• August 11, 2026